call on Thank joining you, today. and good our afternoon, thanks and us Sherry, everyone, for
the discovery forefront being strategy the leadership build product, is We backed to consistent quarter, our the and hasn't channel azetukalner therapeutics. initiate with expansion have X-NOVAX, focus pipeline, of position full mature the only both program portfolio potential this overall further selective and promising as Xenon's maximize as the by III with the over progress indication significant ion as our at represents focused our major encouraging development efficacy continue ion end field And channel MDD lead multiple highly on a with in program Phase is opener proof-of-concept epilepsy disorder.
Within focus of is advancing both potential the data in our our depressive epilepsy Phase our KvX with portfolio, leadership for physician pipeline. of profile in made KvX of communities, continuing azetukalner and raising space of while patients to of through next-generation and long-term position unmatched upon modulators data execution advancement we our key our the past azetukalner, potent in KvX the ion channel to indications potassium clinical development safety to that and channel changed with well patients year of of our areas: azetukalner and before in expected to III patient which expanding azetukalner. living the remain on our of of and azetukalner X
potassium said the channel represents the I development. advanced in unmatched. in most As Xenon's Azetukalner clinical earlier, is landscape late-stage KvX leadership modulator validated clinically
and experience patients. patient efficacy with robust azetukalner XXX in exposure clinical with includes safety substantial focal long-term over of Our years epilepsy data
open-label patients azetukalner we a of our treatment the seizures.
In benefits efficacy favorable in a in represents as best-in-class as X-TOLE double-blind have epilepsy. of potentially shifting quality extension we of our onset with be that clinical paradigm believe well are data the demonstrates study, best from and that generated highly study compelling the X-TOLE believe a that seen could improved in placebo-adjusted experience results we Importantly, ever life medication study seeing anti-seizure We freedom seizure long-term safety patients profile. focal
date, leaders generated that for body the titration, azetukalner mood and to potential key excitement see amassed of could other has mean without benefit.
The to efficacy dosing physicians what the we to compelling from to clinical of the the action to community. need evidence as date novel and of important continues addition once-daily have In such potential rapid generate attributes azetukalner significant they effect, of opinion epilepsy impressive data onset mechanism as
ongoing open-label years X-TOLE OLE have at presentations patients X-TOLE the or an and educate As the have X American Angeles. around been for on taking to continue study.
Patients in years data Meeting, our presence XX exposure Epilepsy azetukalner. with December azetukalner, at results upcoming Society new will through Los place Xenon X We'll now of increased in OLE some AES, we the key stakeholders least having of than the extension have from updated more the benefits to in drug X
as neuropsychiatry, in effect with adverse a freedom is data AES of this compared to to continue rapid month. in drug, filings open-label or significant are for Physicians patients and benefits efficacy medications a favorable molecules of MDD see care are are standard agents, of key better the earlier-stage gain. next this are and weight ability potential sexual We as regulatory product profiles incredibly to at enable our long-term across on the towards seen believe on indications. anhedonia, treat novel support the the of fortunate and pathway will epilepsy longer we commercialization such quality dysfunction other such many other improved differentiator with XX-month and potential avoid effects position data new that in long-term mechanisms address present package that clinical life, to and when We the and looking who seizure or excited an demonstrate including extension, attributes both onset patients and experiencing MDD development.
Further, azetukalner's are in we're
MDD end of beyond planning clinical underway, gears to our year.
Shifting site quarter, last program shared Phase expect the is we azetukalner pipeline. to and we before well this our broader As III initiate
and our multiple Our so discovery experience chemically the team product applied to can that that years neuropsych to the pipeline pain a need goal numerous is therapeutic disorders, we even us to mechanism and indications, across support channels azetukalner IND-enabling more KvX advance ultimately multiple candidates of pipeline, we extending first program ion patients XXXX. IND work NavX.X the therapeutic options.
Today, in meaningful better these conditions or on of many we mechanism in and currently clinical the and development within our from are candidates including reach underway channel make opportunities this well. in seizure our range has progress broad KvX target's candidates to an leverage have continue with its equivalent potential, of diverse providing Staying topic as differentiated in of the of sodium for our pipeline of filing of early-stage
also of of of that correlated non-precipitated are spontaneous an individuals opioids. pain-related class function new not identifying had offered medications proud work in of between burdened who target to perceive genetic the as with This NavX.X gain phenotypes. the with are NavX.X inability the pioneering of pain of associated Xenon's connection We rare pain possibility was liabilities encoding and experienced through individuals that pain was made NavX.X.
Conversely, by mutations. promising identification the important mutations function It a the severe targets loss to of gene who efforts the these complete for
complex novel has a of that advance therapeutics an a believe NavX.X IND of and portfolio by channel to is in we us NavX.X to important targets, pursue enabling while or genetic challenge, ion to the molecules selective modulators. are all the the amongst Currently, candidate we of Importantly, our support gained proof-of-concept within of our development IND-enabling equivalent non-opioid-based lead from certainly pain is far applying pain in filing of derisking generate strongest of development next-generation past medications.
And the NavX.X data. underway knowledge continue validation novel, inhibitors work the goal we with XXXX, development
In other a support preclinical KvX, of precision meeting. development delivering for of spontaneous and the at of small activity potentiators are long-term as some syndrome data, underlying In seizures molecule to Dravet upcoming SUDEP when well strengthening and NavX.X presenting addressing to our Dravet proteins. potentiator We disease-modifying These impacting potentiation neuronal data syndrome against functions in for NavX.X syndrome. specifically other therapy advancing AES NavX.X Dravet with should to therapy. a addition an restore without compelling of etiology support available aim forward look our or including the and medicine protection a we NavX.X as profile compared to and of incredibly drugs hypothesis treat that the NavX.X also
our you. impact, In expertise and Phase already portfolio a advancement for plan I key to the submissions outreach are Matt Boston, his important reiterate, operational preparation Operating as of that, Chris providers as and Finally, broad to to commercial due of Xenon our continued look commercialization. for with commercialization Matthew August stage Ronsheim Chief Dr. pipeline medical R&D progressing programs I'll senior exciting overview to joined and a well over turn has now our executive this pharmaceutical clinical and operations an programs, our time assets. manufacturing positive in progress leadership our strategic as leadership.
With year, early-stage and Chris, care regulatory our ongoing for for it's we over small the our congresses. provide of of brief our development Officer at the Matt's overseeing based azetukalner. made to clinical expand III call molecule providing team as programs and Kenney to of forward extensive of and we programs operational, launch health anticipated as our and continue towards
